Skip to main content
European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

VACCELERATE - European Corona Vaccine Trial Accelerator Platform

Description du projet

Un réseau paneuropéen de développement de vaccins

La pandémie de COVID-19 a souligné la nécessité de mettre en place des efforts concertés dans le développement de vaccins en Europe. Le projet VACCELERATE, financé par l’UE, crée une plateforme connectant toutes les parties prenantes européennes du développement de vaccins. VACCELERATE cartographie les sites d’essais cliniques et de laboratoires en Europe et identifie les meilleurs lieux pour mener des essais de phase 2 et 3 des vaccins. Un registre de volontaires offre un accès aux participants à l’essai. Le réseau coordonne le soutien des laboratoires et propose des tests et des protocoles d’essais normalisés. VACCELERATE identifie et partage les questions de santé publique émergentes, fournit des réponses via ses propres essais cliniques, et apporte son expertise et son soutien concret aux développeurs de vaccins issus des secteurs de l’industrie et de l’université. Grâce à ces efforts, les partenaires de VACCELERATE créent un réseau prêt à lutter contre les pandémies émergentes et à améliorer la capacité de développement de vaccins en Europe.

Objectif

The ongoing COVID-19 pandemic creates an unprecedented burden worldwide. Vaccine-induced immunity is the only promising solution. There is continued need for phase 2 & 3 vaccine trials to reach long-term, large-scale immunity of the entire European population.
VACCELERATE will be the pan-European backbone accelerating phase 2 & 3 COVID-19 vaccine trials. The overall objective of VACCELERATE is to connect all European stakeholders involved in vaccine development to provide a pan-European platform for clinical trial design and conduct. VACCELERATE constitutes the rapid response single entry-point to stakeholders from public health authorities to vaccine developers, to address respective needs and kick-start specifically phase 2 & 3 vaccine trials.
VACCELERATE conducts capacity mapping of clinical trial and laboratory sites to identify suitable sites for individual phase 2 & 3 vaccine trials. Capacity building via training will increase quality in sites across Europe. Volunteer registries facilitate patient recruitment. Access to laboratory sites and a standardised set of assays essential for clinical phase 2 & 3 trials is provided. A harmonised European approach to vaccine trials is enabled by aligning educational standards, coordination of laboratory support and providing standardised assays and trial protocols. Harmonised data collection, open data sharing and pooling of data for stronger analysis enables data standardisation. VACCELERATE offers solutions for characteristic vaccine development issues during pandemics by closing gaps in public health knowledge and improving knowledge transfer.
VACCELERATE amalgamates the vast but scattered expertise across Europe into one network to deliver strategic scientific leadership and guidance on vaccine trials in Europe. Beyond the COVID-19 pandemic, it will be an established pandemic preparedness network, ready to face emerging future pandemics, as well as a pivot in Europe?s capacity to develop vaccines.

Coordinateur

KLINIKUM DER UNIVERSITAET ZU KOELN
Contribution nette de l'UE
€ 8 006 842,72
Adresse
Kerpener Strasse 62
50937 Koeln
Allemagne

Voir sur la carte

Région
Nordrhein-Westfalen Köln Köln, Kreisfreie Stadt
Type d’activité
Higher or Secondary Education Establishments
Liens
Coût total
€ 8 006 842,72

Participants (33)